Distrés respiratorio agudo: del síndrome a la enfermedad

Cardinal-Fernández, Pablo; Correger, Enrique; Villanueva, J.; Ríos, Fernando

doi:10.1016/j.medin.2015.11.006

Cited by 26 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical outcomes after conventional oxygen therapy are modest, and the pathogenesis of the disease remains elusive [ 1 , 2 ]. ARDS manifests as lung edema due to inflammatory alveolar exudate and increased pulmonary vascular permeability, which results in disturbed gas exchange and acute deterioration [ 3 ]. Invasive mechanical ventilation is a common treatment method for patients with ARDS but is associated with certain lung injuries [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

Liu

Wang

Ren

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS). Methods. A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care Medicine at the Fourth Hospital of Baotou from January 2017 to January 2020, and all enrollments were assigned (1 : 1) to receive conventional treatment (control group) or Breztri Aerosphere (study group). Results. Breztri Aerosphere was associated with a significantly higher total efficacy versus conventional treatment. Breztri Aerosphere resulted in significantly lower acute physiology and chronic health evaluation scoring system (APACHE II) scores and Murray lung injury scores versus conventional treatment. Both groups saw an increase in the partial pressure of carbon dioxide (PCO2), partial pressure of oxygen (PO2), and oxygen saturation (SaO2) after treatment, with higher levels seen in patients given Breztri Aerosphere. After treatment, systemic vascular resistance (SVR) in both groups rose markedly, with greater elevation witnessed in the study group. The patients given Breztri Aerosphere showed significantly lower levels of pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (MAPA), pulmonary artery wedge pressure (PAWP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and procalcitonin (PCT) versus those receiving conventional treatment. The patients experienced shorter mechanical ventilation time and intensive care unit (ICU) time after treatment of Breztri Aerosphere versus conventional treatment. Conclusion. Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

Liu

Wang

Ren

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…The clinical, radiological, and histological findings of drug-induced pneumonitis are comparable to those of ARDS (i.e., ground-glass opacities with air bronchograms) [ 2 ]. The early histological features of ARDS are diffuse alveolar damage (DAD), with an initial exudative phase, followed by hyaline membrane formation [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Rifampicin-Induced Pneumonitis Mimicking Severe COVID-19 Pneumonia Infection

et al. 2020

View full text Add to dashboard Cite

Patient: Male, 43-year-old Final Diagnosis: Rifampicin-induced pneumonitis Symptoms: Dyspnea • fatigue • fever Medication: — Clinical Procedure: Bronchoalveolar lavage • bronchoscopy • CT scan • lung biopsy Specialty: Pulmonology Objective: Rare disease Background: Rifampicin-induced pneumonitis is an infrequent occurrence, with only a few cases reported in the literature. Furthermore, this condition constitutes a diagnostic challenge, particularly in the era of COVID-19 infection. Here, we report a case of rifampicin-induced pneumonitis with clinical, imaging, and histological features of acute respiratory distress syndrome (ARDS), which required severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing to exclude a diagnosis of coronavirus disease 2019 (COVID-19) pneumonia. Case Report: A 43-year-old man on anti-TB treatment for TB meningitis developed new-onset fever, fatigue, hypoxemic respiratory failure, and bilateral pulmonary opacities. His clinical, chest X-ray, and CT thorax findings of ARDS were similar to both rifampicin-induced pneumonitis and severe COVID-19 pneumonia. However, reverse transcription polymerase chain reaction (RT-PCR) testing from a nasopharyngeal swab and bronchoalveolar lavage (BAL) via the GeneXpert system was negative for SARS-CoV-2. A detailed workup, including lung biopsy, revealed drug-induced pneumonitis as the cause of his presentation. His pneumonitis improved after discontinuation of rifampicin and recurred following the rifampicin challenge. Conclusions: This case highlights the importance of early, rapid, and accurate testing for SARS-CoV-2 during the COVID-19 pandemic for patients presenting with acute respiratory symptoms, so that accurate diagnosis and early patient management are not delayed for patients with treatable causes of acute and severe lung diseases. Timely identification of rifampicin-induced pneumonitis via a high clinical suspicion, detailed workup, and histopathological analysis is required to avoid permanent damage to the lungs.

show abstract

“…Reports from the United States, Australia, Europe and New Zealand indicate that the incidence of ARDS in the pediatric population is 2 to 12.8 per 100000 patients per year and mortality is found between 27% and 35% [5,7]. Other authors, in different regions incidence of 0.8% to 4.4% and mortality above 50% [6,8]. A 10-year job at a UCIP Cuba, report or 3.6% with overall mortality of 36.7% A retrospective study was conducted on patients admitted to 15 UCIP in 13 provinces of Cuba, which were diagnosed with SDRA, according to the consensus of acute lung damage [4] in the period from January 2016 to December 2018.…”

Section: Introductionmentioning

confidence: 99%

Acute Respiratory Distress Syndrome in Children: Duration of Ventilation and Mortality

S¹,

R²,

Elaine³

et al. 2019

Act Scie Paedia

View full text Add to dashboard Cite

Introduction: Acute respiratory distress syndrome is a disease with severe, progressive and irreversible hypoxemia, of multicausal origin, rare in pediatric intensive units but with high mortality due to multiple organ failure caused by prolonged oxygen deficiency. Results: 282 patients were recorded in the period, 63.7% under the age of six, 54.4% of the male sex and 51.1% of white skin. Clinical forms of lung prevailed (58.1%) and correlate (p-0.022) with survival, the median duration of mechanical ventilation was 10 days. There is a ratio (p-0.000) between ventilation duration and mortality. An overall mortality of 40.78% (n-115) was reported. Conclusions: The acute respiratory distress syndrome has a higher incidence in those under the age of six, in clinical forms of the lungs, which are associated with greater survival, which rises as they increase days of mechanical ventilation. Materials and Methods: Retrospective study of patients admitted to 15 pediatric intensive care units in 13 provinces of Cuba, which were diagnosed with acute respiratory distress, according to the Rome consensus, in the period from January 2016 to December 2018. The data were obtained from each patient's clinical records. Demographic variables, clinical forms of acute respiratory distress syndrome, duration of mechanical ventilation and mortality were evaluated. Qualitative variables are shown in frequency tables by numbers and per cents, in the quantitative variables the classic analysis associated with contingency tab, such as Pearson's ji-square and comparison of stockings. Acute respiratory distress syndrome is a heterogeneous etiology and pathophysiology entity that is severe, progressive and irreversible hypoxemia [1]. For your diagnosis are combined clinical, hemodynamic and oxygenation criteria who were endorsed in Ecc [2] used for many years to identify and treat ARDS in both adult and pediatric patients.

show abstract

Distrés respiratorio agudo: del síndrome a la enfermedad

Cited by 26 publications

References 53 publications

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

Rifampicin-Induced Pneumonitis Mimicking Severe COVID-19 Pneumonia Infection

Acute Respiratory Distress Syndrome in Children: Duration of Ventilation and Mortality

Contact Info

Product

Resources

About